Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 18/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199134 | 0.80 | NR3C1 (0.57) | NR3C1SMOPGRCYP11B2 | |
| SCHEMBL4278587 | 0.79 | NR3C1 (0.66) | NR3C1PGRCYP11B2 | |
| SCHEMBL4273704 | 0.79 | NR3C1 (0.56) | NR3C1PGR | |
| SCHEMBL27724508 | 0.79 | NR3C1 (0.56) | NR3C1SMO | |
| SCHEMBL27724556 | 0.78 | NR3C1 (0.48) | NR3C1CYP11B2 | |
| SCHEMBL27704005 | 0.76 | NR3C1 (0.49) | NR3C1CYP11B2 | |
| SCHEMBL4760701 | 0.76 | SMO (0.56) | NR3C1SMO | |
| SCHEMBL21295429 | 0.76 | NR3C1 (0.54) | NR3C1SMOPGRCYP11B2 | |
| SCHEMBL30918005 | 0.76 | CYP11B2 (0.72) | NR3C1SMOPGRCYP11B2 | |
| SCHEMBL839102 | 0.76 | NR3C1 (0.54) | NR3C1SMOPGRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021203016-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | NR3C1 3867/4885SMO 1389/4885PGR 3527/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | NR3C1 3920/4885SMO 2105/4885PGR 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.